CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
S8 Sinus Implant (mometasone furoate, 1350 mcg)drug
Likely dose
S8 Sinus Implant (mometasone furoate, 1350 mcg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01894503
NCT01894503Phase 2Completed
CompareCT.gov

A Clinical Evaluation of the Safety and Performance of the Steroid-Releasing S8 Sinus Implant When Used in Post-Sinus Surgery Patients With Recurrent Sinus Polyps

Intersect ENT·interventional·Posted Jul 10, 2013·Updated Jul 18, 2018

In Brief

A Phase 2 clinical trial evaluating S8 Sinus Implant (mometasone furoate, 1350 mcg) for Chronic Sinusitis. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The purpose of this study was to assess the safety and performance of the steroid-releasing S8 Sinus Implant when used in post-sinus surgery patients who presented with recurrent sinus obstruction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Sinusitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 10, 2013
Enrollment StartJun 1, 2013
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.0 years ago

Interventions

S8 Sinus Implant (mometasone furoate, 1350 mcg)drug

Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days